CY1110235T1 - Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων - Google Patents

Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων

Info

Publication number
CY1110235T1
CY1110235T1 CY20101100319T CY101100319T CY1110235T1 CY 1110235 T1 CY1110235 T1 CY 1110235T1 CY 20101100319 T CY20101100319 T CY 20101100319T CY 101100319 T CY101100319 T CY 101100319T CY 1110235 T1 CY1110235 T1 CY 1110235T1
Authority
CY
Cyprus
Prior art keywords
cells
dendritic
dendritic cells
immune responses
antigen presenting
Prior art date
Application number
CY20101100319T
Other languages
English (en)
Inventor
Jacques F Banchereau
Frederic Berard
Patrick Blanco
Eve-Marie Neidhart-Berard
Mahyar Nouri-Shirazi
Original Assignee
Baylor Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor Research Institute filed Critical Baylor Research Institute
Publication of CY1110235T1 publication Critical patent/CY1110235T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464494—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Περιγράφονται νέα παρουσιάζοντα αντιγόνα κύτταρα, περιλαμβάνοντα αλλά χωρίς περιορισμό σ' αυτά δενδριτικά κύτταρα (DC), τα οποία είναι φορτισμένα με αντιγόνα από νεκρά ή θνήσκοντα κύτταρα περιλαμβανομένων αλλογενών κυτταρικών σειρών, και οι μέθοδοι παραγωγής τέτοιων παρουσιαζόντων αντιγόνα κυττάρων. Αυτά τα φορτισμένα παρουσιάζοντα αντιγόνα κύτταρα είναι χρήσιμα για την επαγωγή τόσο προφυλακτικών ανοσολογικών αντιδράσεων όσο και θεραπευτικών ανοσολογικών αντιδράσεων σε ανθρώπους. Ειδικότερα, αυτά τα φορτισμένα παρουσιάζοντα αντιγόνα κύτταρα είναι χρήσιμα στην αντιμετώπιση του καρκίνου και μολυσματικών νόσων. Εναλλακτικά, τα φορτισμένα παρουσιάζοντα αντιγόνα κύτταρα μπορούν να χρησιμοποιηθούν για την εξάλειψη των ανεπιθύμητων ανοσολογικών αντιδράσεων όπως αυτοάνοσων αντιδράσεων και της νόσου μοσχεύματος κατά δέκτη ή της αντιδράσεως δέκτη κατά μοσχεύματος, δηλ. της απορρίψεως μοσχεύματος στη μεταμόσχευση οργάνων και μυελού των οστών. Τα παρουσιάζοντα αντιγόνα κύτταρα τα χρήσιμα στην παρούσα εφεύρεση περιλαμβάνουν αλλά δεν περιορίζονται σ' αυτά δενδριτικά κύτταρα σε διάφορα στάδια διαφοροποιήσεως (πρόδρομοι, ανώριμα δενδριτικά κύτταρα και ώριμα δενδριτικά κύτταρα), δενδριτικά κύτταρα προερχόμενα από αρχέγονα κύτταρα αίματος περιλαμβάνοντα αλλά χωρίς περιορισμό σ' αυτά μονοκύτταρα, δενδριτικά κύτταρα προερχόμενα από αρχέγονα αιμοποιητικά κύτταρα CD34, υποσύνολα δενδριτικών κυττάρων όπως κύτταρα Langerhans, ενδιάμεσα DC και λεμφοειδή DC. Τα παρουσιάζοντα αντιγόνα κύτταρα και οι πρόδρομοι κυτταροτοξικών κυττάρων προέρχονται από υγιείς εθελοντές ή από ασθενείς φέροντες όγκους. Τα φορτισμένα με αντιγόνα δενδριτικά
CY20101100319T 1999-10-15 2010-04-07 Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων CY1110235T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15990399P 1999-10-15 1999-10-15
EP00970961A EP1224264B1 (en) 1999-10-15 2000-10-16 Use of allogeneic cell lines to load antigen-presenting cells to elicit immune responses

Publications (1)

Publication Number Publication Date
CY1110235T1 true CY1110235T1 (el) 2015-01-14

Family

ID=22574604

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100319T CY1110235T1 (el) 1999-10-15 2010-04-07 Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων

Country Status (10)

Country Link
US (2) US7988963B1 (el)
EP (3) EP2151245A1 (el)
AT (1) ATE456649T1 (el)
AU (1) AU8026800A (el)
CY (1) CY1110235T1 (el)
DE (1) DE60043781D1 (el)
DK (1) DK1224264T3 (el)
ES (1) ES2340358T3 (el)
PT (1) PT1224264E (el)
WO (1) WO2001029192A2 (el)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040022813A1 (en) * 2002-08-05 2004-02-05 Jean-Claude Bystryn Shed antigen vaccine with dendritic cells adjuvant
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
US8628762B2 (en) * 2008-12-10 2014-01-14 Icahn School Of Medicine At Mount Sinai T-helper cell type 17 lineage-specific adjuvants, compositions and methods
JP2014533938A (ja) 2011-10-20 2014-12-18 カリフォルニア ステム セル インコーポレイテッド γインターフェロンを用いた抗原提示癌ワクチン
WO2016145578A1 (en) * 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
CA3029813A1 (en) 2016-06-13 2017-12-21 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
US11850279B2 (en) 2016-07-13 2023-12-26 Ohio State Innovation Foundation Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637483A (en) 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
ATE260971T1 (de) 1992-04-01 2004-03-15 Univ Rockefeller Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
WO1995032734A1 (en) * 1994-05-26 1995-12-07 Innogenetics N.V. New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
US6300090B1 (en) * 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
EP0879281B1 (en) * 1996-02-08 2005-12-28 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Methods for transforming dendritic cells and activating t cells
DE69816812T2 (de) * 1997-05-23 2004-04-22 Hadasit Medical Research Services And Development Ltd. Non myeloablative therapie für toleranzinduktion
WO1999042564A2 (en) 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
AU2002953094A0 (en) * 2002-12-04 2002-12-19 The University Of Queensland Immunomodulating compositions, processes for their production and uses therefor

Also Published As

Publication number Publication date
EP2302038A1 (en) 2011-03-30
ATE456649T1 (de) 2010-02-15
DK1224264T3 (da) 2010-05-10
US7988963B1 (en) 2011-08-02
AU8026800A (en) 2001-04-30
EP2151245A1 (en) 2010-02-10
US20110268767A1 (en) 2011-11-03
PT1224264E (pt) 2010-03-15
WO2001029192A3 (en) 2002-01-17
EP1224264A2 (en) 2002-07-24
EP1224264B1 (en) 2010-01-27
DE60043781D1 (de) 2010-03-18
ES2340358T3 (es) 2010-06-02
WO2001029192A2 (en) 2001-04-26

Similar Documents

Publication Publication Date Title
CY1110235T1 (el) Χρηση αλλογενετικων κυτταρικων γραμμων για τη φορτωση κυτταρων που εμφανιζουν αντιγονο για την προκληση ή εξαλειψη ανοσολογικων απαντησεων
Hsu et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Shevach CD4+ CD25+ suppressor T cells: more questions than answers
Banchereau et al. Dendritic cells as vectors for therapy
Irvine et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization
EA200000130A1 (ru) Клеточная везикула, называемая "экзосома", ее получение и применение для стимуляции иммунного ответа
PT900380E (pt) Metodos para seleccionar e produzir epitopos peptidicos de celulas t e vacinas que incorporam os referidos epitopos seleccionados
Hellmann et al. Making it personal: neoantigen vaccines in metastatic melanoma
DE69637942D1 (de) Stimulationsfaktor für dendriten
DK1778836T3 (da) Fremstilling af antigenpræsenterende humane gammadelta-T-celler og anvendelse ved immunterapi
JP2011062213A (ja) 樹状細胞の微粒子ベースのトランスフェクションおよび活性化
DE60226853D1 (de) Zelltherapieverfahren für die behandlung von tumoren
Nuber et al. Fine analysis of spontaneous MAGE-C1/CT7–specific immunity in melanoma patients
ITRM20070437A1 (it) Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi
CN109970846A (zh) 一种肿瘤相关抗原XAGE-1b九肽及其应用
JP2013505296A5 (el)
JP2002539805A (ja) 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的ｔ細胞のインビトロ産生
US8097243B2 (en) Microparticle-based transfection and activation of dendritic cells
Panfilis CD8+ cytolytic T lymphocytes and the skin
Sennikov et al. Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A* 02: 01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients
Mortara et al. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions
JP2003514522A5 (el)
Zhou et al. Dendritic cells efficiently acquire and present antigen derived from lung cancer cells and induce antigen-specific T-cell responses
Utermöhlen et al. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8+ cytotoxic T lymphocytes and CD4+ T helper cells
Wang et al. Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro